Cancer Research Grants Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 3192-3198, July 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chang, S. S.
Right arrow Articles by Gaudin, P. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chang, S. S.
Right arrow Articles by Gaudin, P. B.
[Cancer Research 59, 3192-3198, July 1, 1999]
© 1999 American Association for Cancer Research

Tumor Biology

Five Different Anti-Prostate-specific Membrane Antigen (PSMA) Antibodies Confirm PSMA Expression in Tumor-associated Neovasculature1

Sam S. Chang, Victor E. Reuter, W. D. W. Heston, Neil H. Bander, Lana S. Grauer and Paul B. Gaudin2

Urology Service, Department of Surgery [S. S. C.], George M. O’Brien Urology Research Center [W. D. W. H.], and Department of Pathology [V. E. R., P. B. G.], Memorial Sloan-Kettering Cancer Center, New York, New York 10021; Hybritech Incorporated, San Diego, California 92196 [L. S. G.]; and Department of Urology, New York Presbyterian Hospital-Weill Medical College of Cornell University and Ludwig Institute for Cancer Research, New York, New York 10021 [N. H. B.]

Prostate-specific membrane antigen (PSMA) is a type II integral membrane glycoprotein that was initially characterized by the monoclonal antibody (mAb) 7E11. PSMA is highly expressed in prostate secretory-acinar epithelium and prostate cancer as well as in several extraprostatic tissues. Recent evidence suggests that PSMA is also expressed in tumor-associated neovasculature. We examined the immunohistochemical characteristics of 7E11 and those of four recently developed anti-PSMA mAbs (J591, J415, and Hybritech PEQ226.5 and PM2J004.5), each of which binds a distinct epitope of PSMA. Using the streptavidin-biotin method, we evaluated these mAbs in viable prostate cancer cell lines and various fresh-frozen benign and malignant tissue specimens. In the latter, we compared the localization of the anti-PSMA mAbs to that of the anti-endothelial cell mAb CD34. With rare exceptions, all five anti-PSMA mAbs reacted strongly with the neovasculature of a wide spectrum of malignant neoplasms: conventional (clear cell) renal carcinoma (11 of 11 cases), transitional cell carcinoma of the urinary bladder (6 of 6 cases), testicular embryonal carcinoma (1 of 1 case), colonic adenocarcinoma (5 of 5 cases), neuroendocrine carcinoma (5 of 5 cases), glioblastoma multiforme (1 of 1 cases), malignant melanoma (5 of 5 cases), pancreatic duct carcinoma (4 of 4 cases), non-small cell lung carcinoma (5 of 5 cases), soft tissue sarcoma (5 of 6 cases), breast carcinoma (5 of 6 cases), and prostatic adenocarcinoma (2 of 12 cases). Localization of the anti-PSMA mAbs to tumor-associated neovasculature was confirmed by CD34 immunohistochemistry in sequential tissue sections. Normal vascular endothelium in non-cancer-bearing tissue was consistently PSMA negative. The anti-PSMA mAbs reacted with the neoplastic cells of prostatic adenocarcinoma (12 of 12 cases) but not with the neoplastic cells of any other tumor type, including those of benign and malignant vascular tumors (0 of 3 hemangiomas, 0 of 1 hemangioendothelioma, and 0 of 1 angiosarcoma). The mAbs to the extracellular PSMA domain (J591, J415, and Hybritech PEQ226.5) bound viable prostate cancer cells (LNCaP and PC3-PIP), whereas the mAbs to the intracellular domain (7E11 and Hybritech PM2J004.5) did not. All five anti-PSMA mAbs reacted with fresh-frozen benign prostate secretory-acinar epithelium (28 of 28 cases), duodenal columnar (brush border) epithelium (11 of 11 cases), proximal renal tubular epithelium (5 of 5 cases), colonic ganglion cells (1 of 12 cases), and benign breast epithelium (8 of 8 cases). A subset of skeletal muscle cells was positive with 7E11 (7 of 7 cases) and negative with the other four anti-PSMA mAbs. PSMA was consistently expressed in the neovasculature of a wide variety of malignant neoplasms and may be an effective target for mAb-based antineovasculature therapy.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
O. Dakhova, M. Ozen, C. J. Creighton, R. Li, G. Ayala, D. Rowley, and M. Ittmann
Global Gene Expression Analysis of Reactive Stroma in Prostate Cancer
Clin. Cancer Res., June 15, 2009; 15(12): 3979 - 3989.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. B. Apolo, N. Pandit-Taskar, and M. J. Morris
Novel Tracers and Their Development for the Imaging of Metastatic Prostate Cancer
J. Nucl. Med., December 1, 2008; 49(12): 2031 - 2041.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Dhar, F. X. Gu, R. Langer, O. C. Farokhzad, and S. J. Lippard
Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles
PNAS, November 11, 2008; 105(45): 17356 - 17361.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
V. Yao, A. Parwani, C. Maier, W. D. Heston, and D. J. Bacich
Moderate Expression of Prostate-Specific Membrane Antigen, a Tissue Differentiation Antigen and Folate Hydrolase, Facilitates Prostate Carcinogenesis
Cancer Res., November 1, 2008; 68(21): 9070 - 9077.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. A. Rajasekaran, J. J. Christiansen, I. Schmid, E. Oshima, K. Sakamoto, J. Weinstein, N. P. Rao, and A. K. Rajasekaran
Prostate-specific membrane antigen associates with anaphase-promoting complex and induces chromosomal instability
Mol. Cancer Ther., July 1, 2008; 7(7): 2142 - 2151.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. C. Mease, C. L. Dusich, C. A. Foss, H. T. Ravert, R. F. Dannals, J. Seidel, A. Prideaux, J. J. Fox, G. Sgouros, A. P. Kozikowski, et al.
N-[N-[(S)-1,3-Dicarboxypropyl]Carbamoyl]-4-[18F]Fluorobenzyl-L-Cysteine, [18F]DCFBC: A New Imaging Probe for Prostate Cancer
Clin. Cancer Res., May 15, 2008; 14(10): 3036 - 3043.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
P. Mhawech-Fauceglia, D. J. Smiraglia, W. Bshara, C. Andrews, J. Schwaller, S. South, D. Higgs, S. Lele, F. Herrmann, and K. Odunsi
Prostate-Specific Membrane Antigen Expression Is a Potential Prognostic Marker in Endometrial Adenocarcinoma
Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 571 - 577.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Balhorn, S. Hok, P. A. Burke, F. C. Lightstone, M. Cosman, A. Zemla, G. Mirick, J. Perkins, A. Natarajan, M. Corzett, et al.
Selective High-Affinity Ligand Antibody Mimics for Cancer Diagnosis and Therapy: Initial Application to Lymphoma/Leukemia
Clin. Cancer Res., September 15, 2007; 13(18): 5621s - 5628s.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Rege, S. J. Patel, Z. Megeed, and M. L. Yarmush
Amphipathic Peptide-Based Fusion Peptides and Immunoconjugates for the Targeted Ablation of Prostate Cancer Cells
Cancer Res., July 1, 2007; 67(13): 6368 - 6375.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. J. Durso, S. Andjelic, J. P. Gardner, D. J. Margitich, G. P. Donovan, R. R. Arrigale, X. Wang, M. F. Maughan, T. L. Talarico, R. A. Olmsted, et al.
A Novel Alphavirus Vaccine Encoding Prostate-Specific Membrane Antigen Elicits Potent Cellular and Humoral Immune Responses
Clin. Cancer Res., July 1, 2007; 13(13): 3999 - 4008.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. J. Morris, N. Pandit-Taskar, C. R. Divgi, S. Bender, J. A. O'Donoghue, A. Nacca, P. Smith-Jones, L. Schwartz, S. Slovin, R. Finn, et al.
Phase I Evaluation of J591 as a Vascular Targeting Agent in Progressive Solid Tumors
Clin. Cancer Res., May 1, 2007; 13(9): 2707 - 2713.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. I. Milowsky, D. M. Nanus, L. Kostakoglu, C. E. Sheehan, S. Vallabhajosula, S. J. Goldsmith, J. S. Ross, and N. H. Bander
Vascular Targeted Therapy With Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Advanced Solid Tumors
J. Clin. Oncol., February 10, 2007; 25(5): 540 - 547.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Aggarwal, P. Singh, O. Topaloglu, J. T. Isaacs, and S. R. Denmeade
A dimeric Peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity.
Cancer Res., September 15, 2006; 66(18): 9171 - 9177.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
R. E. Conway, N. Petrovic, Z. Li, W. Heston, D. Wu, and L. H. Shapiro
Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction.
Mol. Cell. Biol., July 1, 2006; 26(14): 5310 - 5324.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Ma, C. E. Hopf, A. D. Malewicz, G. P. Donovan, P. D. Senter, W. F. Goeckeler, P. J. Maddon, and W. C. Olson
Potent Antitumor Activity of an Auristatin-Conjugated, Fully Human Monoclonal Antibody to Prostate-Specific Membrane Antigen
Clin. Cancer Res., April 15, 2006; 12(8): 2591 - 2596.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. Castelletti, G. Fracasso, M. Alfalah, S. Cingarlini, M. Colombatti, and H. Y. Naim
Apical Transport and Folding of Prostate-specific Membrane Antigen Occurs Independent of Glycan Processing
J. Biol. Chem., February 10, 2006; 281(6): 3505 - 3512.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. J. Morris, C. R. Divgi, N. Pandit-Taskar, M. Batraki, N. Warren, A. Nacca, P. Smith-Jones, L. Schwartz, W. K. Kelly, S. Slovin, et al.
Pilot Trial of Unlabeled and Indium-111-Labeled Anti-Prostate-Specific Membrane Antigen Antibody J591 for Castrate Metastatic Prostate Cancer
Clin. Cancer Res., October 15, 2005; 11(20): 7454 - 7461.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. A. Foss, R. C. Mease, H. Fan, Y. Wang, H. T. Ravert, R. F. Dannals, R. T. Olszewski, W. D. Heston, A. P. Kozikowski, and M. G. Pomper
Radiolabeled Small-Molecule Ligands for Prostate-Specific Membrane Antigen: In vivo Imaging in Experimental Models of Prostate Cancer
Clin. Cancer Res., June 1, 2005; 11(11): 4022 - 4028.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
A. K. Rajasekaran, G. Anilkumar, and J. J. Christiansen
Is prostate-specific membrane antigen a multifunctional protein?
Am J Physiol Cell Physiol, May 1, 2005; 288(5): C975 - C981.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
H. Zeng, Q. Wu, H. Li, Q. Wei, Y. Lu, X. Li, F. Wang, F. Zhao, Z. Ding, and Y. Yang
Construction of Prostate-Specific Expressed Recombinant Plasmids With High Transcriptional Activity of Prostate-Specific Membrane Antigen (PSMA) Promoter/Enhancer
J Androl, March 1, 2005; 26(2): 215 - 221.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
A. M. Velasco, K. A. Gillis, Y. Li, E. L. Brown, T. M. Sadler, M. Achilleos, L. M. Greenberger, P. Frost, W. Bai, and Y. Zhang
Identification and Validation of Novel Androgen-Regulated Genes in Prostate Cancer
Endocrinology, August 1, 2004; 145(8): 3913 - 3924.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. E. Lupold and R. Rodriguez
Disulfide-constrained peptides that bind to the extracellular portion of the prostate-specific membrane antigen
Mol. Cancer Ther., May 1, 2004; 3(5): 597 - 603.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. S. Ross, C. E. Sheehan, H. A. G. Fisher, R. P. Kaufman Jr., P. Kaur, K. Gray, I. Webb, G. S. Gray, R. Mosher, and B. V. S. Kallakury
Correlation of Primary Tumor Prostate-Specific Membrane Antigen Expression with Disease Recurrence in Prostate Cancer
Clin. Cancer Res., December 15, 2003; 9(17): 6357 - 6362.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Biol. CellHome page
S. A. Rajasekaran, G. Anilkumar, E. Oshima, J. U. Bowie, H. Liu, W. Heston, N. H. Bander, and A. K. Rajasekaran
A Novel Cytoplasmic Tail MXXXL Motif Mediates the Internalization of Prostate-specific Membrane Antigen
Mol. Biol. Cell, December 1, 2003; 14(12): 4835 - 4845.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
N. Schulke, O. A. Varlamova, G. P. Donovan, D. Ma, J. P Gardner, D. M. Morrissey, R. R. Arrigale, C. Zhan, A. J. Chodera, K. G. Surowitz, et al.
The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy
PNAS, October 28, 2003; 100(22): 12590 - 12595.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Schroers, L. Shen, L. Rollins, Z. Xiao, G. Sonderstrup, K. Slawin, X. F. Huang, and S.-Y. Chen
Identification of MHC Class II-restricted T-cell Epitopes in Prostate-specific Membrane Antigen
Clin. Cancer Res., August 1, 2003; 9(9): 3260 - 3271.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. A. Khan and A. W. Partin
Management of High-Risk Populations with Locally Advanced Prostate Cancer
Oncologist, June 1, 2003; 8(3): 259 - 269.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. T. Thomas, P. T. Bradshaw, B. H. Pollock, J. E. Montie, J. M.G. Taylor, H. D. Thames, P. W. McLaughlin, D. A. DeBiose, D. H. Hussey, and R. L. Wahl
Indium-111-Capromab Pendetide Radioimmunoscintigraphy and Prognosis for Durable Biochemical Response to Salvage Radiation Therapy in Men After Failed Prostatectomy
J. Clin. Oncol., May 1, 2003; 21(9): 1715 - 1721.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
P. M. Smith-Jones, S. Vallabhajosula, V. Navarro, D. Bastidas, S. J. Goldsmith, and N. H. Bander
Radiolabeled Monoclonal Antibodies Specific to the Extracellular Domain of Prostate-Specific Membrane Antigen: Preclinical Studies in Nude Mice Bearing LNCaP Human Prostate Tumor
J. Nucl. Med., April 1, 2003; 44(4): 610 - 617.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. F. Shariat, M. W. Kattan, S. Erdamar, C. Nguyen, P. T. Scardino, D. M. Spencer, T. M. Wheeler, and K. M. Slawin
Detection of Clinically Significant, Occult Prostate Cancer Metastases in Lymph Nodes Using a Splice Variant-Specific RT-PCR Assay for Human Glandular Kallikrein
J. Clin. Oncol., April 1, 2003; 21(7): 1223 - 1231.
[Abstract] [Full Text] [PDF]

Home page
 Cell Growth Differ.Home page
S. H. Lang, M. Stark, A. Collins, A. B. Paul, M. J. Stower, and N. J. Maitland
Experimental Prostate Epithelial Morphogenesis in Response to Stroma and Three-Dimensional Matrigel Culture
Cell Growth Differ., December 1, 2001; 12(12): 631 - 640.
[Abstract] [Full Text] [PDF]

Home page
 PhysiologyHome page
C. Halin, L. Zardi, and D. Neri
Antibody-Based Targeting of Angiogenesis
Physiology, August 1, 2001; 16(4): 191 - 194.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. R. McDevitt, E. Barendswaard, D. Ma, L. Lai, M. J. Curcio, G. Sgouros, A. M. Ballangrud, W.-H. Yang, R. D. Finn, V. Pellegrini, et al.
An {{alpha}}-Particle Emitting Antibody ([213Bi]J591) for Radioimmunotherapy of Prostate Cancer
Cancer Res., November 1, 2000; 60(21): 6095 - 6100.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
P. M. Smith-Jones, S. Vallabahajosula, S. J. Goldsmith, V. Navarro, C. J. Hunter, D. Bastidas, and N. H. Bander
In Vitro Characterization of Radiolabeled Monoclonal Antibodies Specific for the Extracellular Domain of Prostate-specific Membrane Antigen
Cancer Res., September 1, 2000; 60(18): 5237 - 5243.
[Abstract] [Full Text]

Home page
 CarcinogenesisHome page
R. S. Kerbel
Tumor angiogenesis: past, present and the near future
Carcinogenesis, March 1, 2000; 21(3): 505 - 515.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. S. Chang, D. S. O'Keefe, D. J. Bacich, V. E. Reuter, W. D. W. Heston, and P. B. Gaudin
Prostate-specific Membrane Antigen Is Produced in Tumor-associated Neovasculature
Clin. Cancer Res., October 1, 1999; 5(10): 2674 - 2681.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.